Subscribe
shutterstock_300670976_-aleksandr-kurganov
Aleksandr Kurganov / Shutterstock.com
24 December 2020AmericasMuireann Bolger

Canopy sues GW Pharma over cannabis patent

Canadian medical cannabis company  Canopy Growth has accused  GW Pharma of using a patented technological process to produce its flagship epilepsy treatment,  Epidiolex, without authorisation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Canadian cannabis brand blocked from UK TM registration
7 February 2020   The UK Intellectual Property Office has blocked Canadian brand Vivo Cannabis from registering ‘Lumina’ as a trademark, after an opposition from an Italian pharmaceutical company.
Plant Varieties
The race to patent psychoactives
18 May 2021   Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent.
article
Fed Circuit to address cannabis clash
5 July 2022   The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Europe
Canadian cannabis brand blocked from UK TM registration
7 February 2020   The UK Intellectual Property Office has blocked Canadian brand Vivo Cannabis from registering ‘Lumina’ as a trademark, after an opposition from an Italian pharmaceutical company.
Plant Varieties
The race to patent psychoactives
18 May 2021   Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent.
article
Fed Circuit to address cannabis clash
5 July 2022   The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment.

More on this story

Europe
Canadian cannabis brand blocked from UK TM registration
7 February 2020   The UK Intellectual Property Office has blocked Canadian brand Vivo Cannabis from registering ‘Lumina’ as a trademark, after an opposition from an Italian pharmaceutical company.
Plant Varieties
The race to patent psychoactives
18 May 2021   Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent.
article
Fed Circuit to address cannabis clash
5 July 2022   The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York